Dr Curtis Rambaran is a physician/scientist who received his medical degree from the University of the West Indies, Trinidad and completed his residency in Internal Medicine in Yorkshire, United Kingdom (UK). He was then awarded the prestigious Wellcome Trust Cardiovascular (CV) Research fellowship at Kings College London to study the ethnic differences in vascular structure and function between UK and Caribbean patients. His specialty training in CV Medicine and Clinical Pharmacology followed at Guys & St Thomas Hospital, London. In 2009 he joined the Translational Medicine team at GlaxoSmithKline leading first in human/experimental medicine studies for novel compounds targeting vascular inflammation, severe asthma and COPD. Subsequently he was the medical governance lead for the LATITUDE-TIMI 60 Phase 3 CV outcome study of oral MAP Kinase inhibition in ACS subjects. In 2015, he became the European Head of Translational Medicine/Clinical Pharmacology at Daiichi Sankyo, UK and in 2016 he relocated to the East coast USA as Senior Director CV Therapeutic area at Daiichi Sankyo Inc (DSI).
As global team leader in the US, he led to completion a clinical development program for a novel cardio-renal asset targeting CKD through Phase1 b/POC studies. He is currently the DSI Cardio-Renal category lead providing clinical leadership for stem cell CV programs including iPSC and MSC therapies for Heart Failure. He is also global clinical lead for rare disease programs of high unmet medical need including antisense oligonucleotide approaches to Duchene Muscular Dystrophy and is the DSI representative on the Cardiac Safety Research Consortium (CSRC).